After exclusion of women with less than 12 months of follow-up or those who were HPV-16 / 18 DNA-positive at enrolment ( for the HPV-16 / 18 endpoint ) , we calculated vaccine efficacy against one-time detection of incident HPV infections after three , two , and one dose ( s ) .